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OBJECTIVE: The study objective was to reduce aluminum (Al) in Calcium Gluconate Injection, US Pharmacopeia (USP) used in the preparation of parenteral nutrition (PN) solutions.
METHODS: A flow-through filter containing an immobilized chelator that complexes Al from Calcium
Gluconate Injection, USP as it flows through the filter was designed, refined by design modifications, and
extensively tested. When a small-volume parenteral vial containing 100 mL of Calcium Gluconate Injection,
USP is connected on the inlet side of the filter, and the outlet side is connected to an evacuated receiving
vial, the filtered solution is drawn into the receiving vial. This constitutes a complete system to remove Al
from Calcium Gluconate Injection, USP.
RESULTS: The extent of Al removal is flow rate dependent. At a flow rate of 1 mL/min approximately 85%
of the Al was removed from calcium gluconate solution. PN solutions have been reported to deliver 15 to
23 mcg/kg/day Al to neonates. Given that Calcium Gluconate Injection, USP provides 85% of the Al in neonatal PN solutions, removal of 85% of the Al from this source was calculated to reduce Al delivered to most
neonates to <5 mcg/kg/day.
CONCLUSIONS: A point-of-use, self-contained, single-use, disposable, Al-complexing filter has been created. It was calculated to reduce Al delivered in PN solutions by 72%, resulting in daily Al delivery below the
level that results in Al accumulation associated with central nervous system and bone toxicity to all but the
smallest (<1 kg) infants.
INDEX TERMS: aluminum, calcium gluconate, parenteral nutrition
J Pediatr Pharmacol Ther 2014;19(3):189–195

INTRODUCTION
Aluminum (Al) is a contaminant of small- and
large-volume parenteral (SVP and LVP) solutions used to compound parenteral nutrition
(PN) solutions. It produces no beneficial effects
in the human but has the potential to produce
toxicity to the brain, skeletal system, liver, and
erythropoietic system. Premature neonates are
the population at greatest risk for Al toxicity
because of their immature renal function (the
primary route of Al elimination). A standard
PN solution that delivered 45 mcg/kg/day Al
was given to premature neonates for about 10
J Pediatr Pharmacol Ther 2014 Vol. 19 No. 3 • www.jppt.org

days and resulted in significant reduction in the
Bayley Mental Development Index score at age
18 months compared with infants who received
approximately 15% as much Al.1 A follow-up
study a decade later showed the children who
received the PN solution that delivered 45 mcg/
kg/day Al had less lumbar spine bone mineral
content than those who received 15% as much
Al.2 Al may contribute to the vitamin D–resistant
rickets seen in neonates given PN.3,4 Al in PN
solution may also contribute to cholestasis.5,6 A
microcytic, hypochromic anemia that appears in
adult dialysis patients7 correlates with plasma
Al concentration.8 This has been associated with
189
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elevated Al in pediatric patients,9 but the association of anemia and Al exposure has evidently not
been investigated in neonates.
The amount of Al given to neonates in PN solutions was estimated10,11 based on the maximum
Al content stated on the product label, which
ranged up to 12,500 mcg/L. Such calculations do
not document the actual amount of Al delivered
to neonates by PN, given that the product’s Al
concentration may be considerably less than the
maximum stated on its label.
Al delivered to 10 neonatal patients weighing
1.5 to 2.5 kg was determined by quantifying
the Al in prepared PN solutions. This showed
a mean ± SD of 15.2 ± 8.0 mcg/kg/day.12 Based
on Al eliminated in the urine, 56% of the intake
was retained by these infants. Similarly, the measured Al in PN solutions given to 40 neonates
revealed a mean daily delivery ranging from 23
mcg/kg in patients weighing <1 kg to 15 mcg/
kg in 4- to 6-kg patients.13 This level of Al delivery is well above the 4 to 5 mcg/kg/day Al load
that results in Al accumulation associated with
central nervous system and bone toxicity noted
in the Food and Drug Administration’s (FDA’s)
labeling requirement that addresses Al in SVP
and LVP solutions.14
The Al concentration of PN components and
prepared PN solutions is not routinely quantified before their use. As a result, the amount
of Al given to patients is not routinely known.
The main source of the Al in PN solutions is
Calcium Gluconate Injection, US Pharmacopeia
(USP), which was shown to contribute 78% to
89% of the Al in PN solutions.15–18 Al increases
over time in calcium gluconate packaged in
glass vials because of the Al complexing ability
of gluconate, which leaches Al from the glass
storage container.19,20 The clinical problem of Al
contamination in components used to compound
PN solutions has been recognized for nearly 30
years. It was recently reviewed21–24 and presented
at an international aluminum conference.25
To reduce the amount of Al delivered to
neonates, it was suggested to use component
SVP and LVP solutions that have the smallest
maximum Al concentration according to the
product label, and to minimize the shelf life of
calcium gluconate.10,23,26 Even with use of these
approaches it is currently not possible to bring
the Al delivered to neonates by PN to less than
4 to 5 mcg/kg/day.21,23 To address this problem
190
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we developed a filter that removes most of the Al
from Calcium Gluconate Injection, USP.

MATERIALS AND METHODS
To reduce the amount of Al delivered in PN
solutions, we considered the steps in the PN
preparation process amenable to Al removal,
the preferable method of Al removal, and the application of that method. Selective removal of Al
from the compounded PN solution was deemed
not possible because there were no known methods to remove Al without also removing essential
trace metals, such as iron and copper. The focus
was then on Al removal from its primary source,
Calcium Gluconate Injection, USP. Removal of
Al by complexation to an immobilized chelator (resin), so that the chelator did not enter the
calcium gluconate solution, was selected as the
most practical approach. Consideration of both
Al complexing ability by the chelator and ease of
synthesis suggested incorporation of hydroxamic
acid, the functional moiety of desferrioxamine
(deferoxamine), used clinically to reduce Al accumulation and toxicity.27,28
The ligand exchange rate for Al is rather slow,29
and the rate of calcium gluconate addition to PN
solutions as they are being prepared by commercial compounders is very high. Therefore, it was
concluded that Al extraction efficiency would
probably be very low if the resin were exposed to
the Al-contaminated calcium gluconate solution
flowing at this high rate. This was confirmed by
preliminary studies using a simple flow-through
cartridge containing the resin that showed an
inverse relationship between flow rate and Al
extraction efficiency. This dictated a point of application that was off-line from the preparation of
PN solution (not used in-line between the calcium
gluconate source and the bag containing the PN
being prepared). We investigated several concepts. The use of a recirculating peristaltic/roller
or syringe pump to push the calcium gluconate
through a cartridge containing the resin had the
disadvantages of the required equipment, the
requirement to validate electrical/power compliance, the need for the person using the pump to
select the proper flow rate, and the need for the
pump to automatically stop at the end of filtration.
Space constraints in the laminar flow hood were
also of major concern with this approach. A “tea
bag” approach in which the resin would be conJ Pediatr Pharmacol Ther 2014 Vol. 19 No. 3 • www.jppt.org
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tained in a semipermeable membrane (bag) was
found to benefit from agitation for good efficiency.
However, this would require auxiliary equipment,
a bag in a bottle is not standard practice in the
hospital’s IV/PN preparation room, and there was
concern the bag may occlude the outlet when the
calcium gluconate solution was withdrawn. We
investigated loose resin beads in a vial that would
receive the calcium gluconate. The resin beads
would have to be retained by a membrane. We
considered that the end users might be concerned
that the membrane did not retain all of the beads.
We found greater Al extraction with the resin in a
flow-through cartridge compared with a suspension of the resin in the calcium gluconate.
As an alternative to pushing the calcium gluconate through the resin, we investigated using
partial vacuum to pull it through a cartridge containing the resin. This was achieved using a partially evacuated receiving vial to pull the calcium
gluconate solution through a cartridge containing
the resin, and a flow restrictor to control the fluid
flow rate (the ALKYMOS ACE filter, ALKYMOS
Inc, Lexington, KY). This approach requires no additional equipment. A flow rate of 1 mL/min was
selected as a compromise between the increased
Al extraction efficiency achieved with longer
extraction time and the resultant duration of the
extraction. This flow rate requires 100 minutes to
remove Al from 100 mL of calcium gluconate. This
approach was tested with commercial Calcium
Gluconate Injection, USP, 100-mL vials (from
APP Pharmaceuticals LLC, Schaumburg, IL) and
Calcium Gluconate Injection, USP to which additional Al was added to approach the maximum
Al concentration of some Calcium Gluconate
Injection, USP products (12,500 mcg/L). This
was accomplished by adding Al (as the nitrate) to
give higher initial Al concentrations of 8000 and
11,500 mcg/L and allowing equilibration for >1
week. The Al concentration was quantified using
inductively coupled plasma mass spectrometry
(Agilent 7500cx, Santa Clara, CA).
The above experiments were conducted with
non–gamma-irradiated filters. In addition, 3
filters were exposed to 25-kGy and 3 filters to 50kGy gamma irradiation, and Al and calcium concentrations before and after filtration of Calcium
Gluconate Injection, USP were determined using
inductively coupled plasma mass spectrometry.
Results were compared to a standard curve created from an Ultra Scientific (N. Kingstown, RI)
J Pediatr Pharmacol Ther 2014 Vol. 19 No. 3 • www.jppt.org

Figure 1. Percentage of aluminum removed from commercial Calcium Gluconate Injection, USP by the ALKYMOS
ACE filter. Results are from 4 separate experiments, each
conducted with 2 to 4 replicates.

Analytical Solutions multielement standard. A
PlasmaCAL multielement calibration standard
(SCP Science, Champlain, NY) was used to prepare the intercalibration verification standard.
Scandium was added as the internal standard to
all samples and standards for the Al and calcium
analyses.
Using the extent of Al extraction from Calcium Gluconate Injection, USP by the gammasterilized ALKYMOS ACE filters, we calculated
the reduction in total Al exposure expected in
patients receiving PN solutions, assuming that
85% (based on the 78%-89% described in the
introduction15–18) of the Al in PN solutions is
derived from Calcium Gluconate Injection, USP.
Poole et al13 measured the Al delivered to 40 neonates receiving PN. The calculated Al exposure
reduction was applied to the results of Poole et
al13 to predict the Al load that would be delivered
to neonates if the ALKYMOS ACE filter was used.

RESULTS
The commercial Calcium Gluconate Injection,
USP contained 3200 to 4500 mcg/L Al. More than
90% of the Al from 100 mL of this product was
removed by the ALKYMOS ACE filter (Figure 1).
When the Al concentration of Calcium Gluconate
Injection, USP was 8000 or 11,500 mcg/L (after
addition of Al nitrate), the filter still removed
≥85% of the Al (Figure 2). Al removal rates were
87% and 84% by 25- and 50-kGy gamma-sterilized filters, respectively. The calcium concentra191
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Figure 2. Percentage of aluminum (Al) removed from commercial Calcium Gluconate Injection, USP, to which Al was
added, by the ALKYMOS ACE filter. Dashed vertical line is
maximum commercial product Al concentration. Results
are the 2 replicates at each concentration.

tions after filtration through filters exposed to
25- and 50-kGy gamma irradiation were 100%
and 101%, respectively. Assuming removal of
85% of the Al from calcium gluconate, which is
contributing 85% of the Al in prepared PN solutions,15–18 we calculate that the ALKYMOS ACE
filter should reduce Al in the PN solution by 72%.
Two examples illustrate the amount of Al that
can be removed using the ALKYMOS ACE filter.
Among infants weighing between 1 and 6 kg
in the Poole et al13 study, those weighing 1 to 2
kg were exposed to the highest average Al load
(17.62 mcg/kg/day). Using the ALKYMOS ACE
filter, which should reduce Al by 72%, the daily
Al exposure would be 4.9 mcg/kg/day (Figure
3). For infants weighing less than 1 kg, Poole et
al13 reported Al exposure of 23.11 mcg/kg/day.
After calcium gluconate filtration, Al load should
be reduced to 6.4 mcg/kg/day. So this filtration
system will allow for daily Al delivery below the
level that results in Al accumulation associated
with central nervous system and bone toxicity,
except for those infants who weigh less than 1
kg or who have an extraordinarily high calcium
requirement.

DISCUSSION
Several concepts were considered and investigated to remove Al from Calcium Gluconate
Injection, USP using an immobilized chelator
(resin). Numerous prototypes were tested to de192

Figure 3. Predicted aluminum (Al) in PN solutions prepared with ALKYMOS ACE–filtered calcium gluconate. Al
delivered daily to patients by parenteral nutrition (PN)
from Poole et al13 (black filled histograms) and the calculated daily Al load, assuming that calcium gluconate
contributes 85% of the total Al to PN and that 85% of the
Al from calcium gluconate is removed by filtration through
the ALKYMOS ACE filter (open histograms), compared with
the 5 mcg/kg/day Food and Drug Administration guideline
(horizontal dashed line).

termine the influence of flow rate, concept, and
calcium gluconate Al concentration on Al extraction. A filter containing the resin through which
Calcium Gluconate Injection, USP was drawn
showed the greatest reduction of Al, >90%. Filters
sterilized by gamma irradiation removed 85% of
the Al. This process required no auxiliary equipment and was completed in less than 2 hours.
This approach has the potential to address the
long-standing concern regarding the amount
of Al delivered in PN solutions, particularly to
premature neonates. This approach focuses on reduction of Al in the primary source contributing
Al to PN solutions, Calcium Gluconate Injection,
USP. Premature neonates are at greatest risk of
Al accumulation and potential toxicity because of
their incompletely developed renal function and
high calcium requirement. This long-recognized
problem has not been adequately resolved. In
1986 an FDA Advisory Panel recommended
that Al be eliminated from components of PN
solutions.30 After three open meetings to discuss
this issue,31 the FDA published in 1990 a Notice
of Intent to establish a labeling requirement. In
1998, the FDA proposed a rule, “Aluminum in
Large and Small Volume Parenterals Used in
Total Parenteral Nutrition,” to amend its labelJ Pediatr Pharmacol Ther 2014 Vol. 19 No. 3 • www.jppt.org
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Figure 4. (A) A schematic diagram of the ALKYMOS ACE filter. (B) The ALKYMOS ACE filter system and a commercial
vial of Calcium Gluconate Injection, USP during filtration of the calcium gluconate solution. (C) The ALKYMOS ACE filter
system and a commercial vial of Calcium Gluconate Injection, USP during filtration, to illustrate the space requirement
for this process.

ing requirement. The rule noted that “levels of
aluminum at greater than 4 to 5 mcg/kg/day
accumulate with central nervous system and
bone toxicity,”32 set an upper limit of 25 mcg/L
(0.90 μM) of Al in LVPs used in PN, and required
a statement of the maximum Al concentration in
SVPs at expiry. The information was intended
to allow health care professionals to calculate a
patient’s exposure to Al when receiving PN and
to take actions that limit intake in patients susceptible to Al toxicity. After 3 delays, the rule was
implemented on July 26, 2004, as 21CFR(201.323),
and was updated in 2012.14 The delays were due
to concerns expressed by SVP manufacturers that
they were probably not meeting the limit and that
it may be difficult to do so.33 The Al content of
PN solutions still exceeds the FDA safe level.12,13
Furthermore, the Al content of PN solutions
cannot be accurately determined by calculation
based on the maximum Al content of components
used to compound the PN solution.13 Calcium
gluconate solution Al content increases over
time when it is stored in a glass vial, because of
leaching of Al from the glass.19 This increase was
observed during conduct of the present study.
Therefore, a statement of Al content in Calcium
Gluconate Injection, USP at the time of release,
as suggested,26 would not provide information
about the Al concentration at the time of use.
Because it is not practical to routinely quantify
Al in prepared PN solutions, or even Calcium
Gluconate Injection, USP prior to PN administration, health care professionals are delivering an
J Pediatr Pharmacol Ther 2014 Vol. 19 No. 3 • www.jppt.org

unknown amount of Al to their patients.
It was suggested to add desferrioxamine to PN
solutions to complex the Al as aluminoxamine,
which would presumably be eliminated in the
urine, assuming adequate renal function to do
so.34 However, this would potentially expose the
patient to desferrioxamine, which has considerable adverse effects. Desferrioxamine complexes
trivalent metals and forms a stronger coordination bond with iron than Al,35 potentially reducing iron and other essential metals. The present
approach uses the same functional group as
desferrioxamine (hydroxamic acid) to remove
the Al before it enters the PN solution.

CONCLUSIONS
The ACE filter, developed by ALKYMOS,
draws Calcium Gluconate Injection, USP from
the commercial SVP vial through a cartridge containing hydroxamic acid–containing resin into
an evacuated receiving vial. The low-Al calcium
gluconate solution from the receiving vial would
then be used to prepare PN solutions. The Al
removal process is conducted off-line and can be
initiated prior to PN preparation so that it does
not interfere with or have a direct impact on PN
preparation, and the filtered calcium gluconate
is ready to use when PN compounding begins.
This pharmaceutical compounding process takes
2 hours. Multiple vials can be filtered simultaneously. The space required is quite small and is
above the working counter of the laminar flow
193
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hood, so that multiple filtration systems could
be operating while other activities are ongoing
in the laminar flow hood (Figure 4). The filtration process should be initiated at the onset of
PN preparation setup so that the filtered calcium
gluconate solution will be available 2 hours later
when PN preparation begins.
The ALKYMOS ACE filter is a point-of-use,
self-contained, single-use, disposable, Al-complexing filter. It has been shown to remove 85%
of the Al from Calcium Gluconate Injection, USP.
It should reduce Al delivered in PN solutions
by 72%, resulting in daily Al delivery below the
level considered toxic to all but the smallest (<1
kg) infants. This filter system fills a void because
currently there are no commercially available options to reduce Al for the pharmacist to employ
to extract Al from pediatric and neonatal PN.
Disclosure Robert A. Yokel, Wesley R. Harris, Christopher
D. Spilling, and Robert J. Kuhn are ALKYMOS shareholders.
Robert A. Yokel has full access to all of the data in the study
and takes responsibility for the integrity of the data and
the accuracy of the data analysis.
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